Increased concentration of matrix metalloproteinase-9 in serum of COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 54s Year: 2005
High MMP-9 activity characterises pleural tuberculosis correlating with granuloma formation Source: Eur Respir J 2009; 33: 134-141 Year: 2009
Matrix metalloproteinase-9 (MMP-9) elevated in serum, but not in bronchial lavage in lung cancer patients Source: Eur Respir J 2005; 26: Suppl. 49, 328s Year: 2005
Relationship between circulating serpina 3g, activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1, 2 with chronic obstructive pulmonary disease severity Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018
Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients Source: Eur Respir J 2005; 25: 885-890 Year: 2005
Sputum matrix metalloproteinase-9 and tissue inhibitor of matrix metalloprotienase-1 levels in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 651s Year: 2006
The role of matrix metalloproteinase- 9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMMP-1) in sarcoidosis and idiopathic pulmonary fibrosis. Correlation with echocardiography Source: Eur Respir J 2006; 28: Suppl. 50, 745s Year: 2006
Matrix metalloproteinases (MMPs) and angiogenesis in lung tissue remodeling in different variants of idiopathic interstitial pneumonia (IIP) Source: Eur Respir J 2007; 30: Suppl. 51, 137s Year: 2007
Elevated level of circulating matrix metalloproteinase-9 in non-small lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 229s Year: 2002
Impact of acute exposure to tobacco smoke on gelatinases in the bronchoalveolar space Source: Eur Respir J 2008; 32: 644-650 Year: 2008
Effect of recombinant α-1 antitrypsin (rAAT) and TAPI on neutrophil elastase (NE) and matrix metalloproteinase-9 (MMP9) activity in induced sputum (IS) from healthy smokers and patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2003 - Progress on therapy for chronic obstructive pulmonary disease Year: 2003
Remodelling of extracellular matrix (ECM) differs between tumor centre and invasion front in human non-small cell lung cancer: immunohistochemistry and morphometry of matrix proteins (MP), matrix metalloproteinases (MMPs), and tissue inhibitors of MMPs (T Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases Year: 2008
Expression of matrix metalloproteinases and TIMP inhibitors in circulation/lung in patients with chronic obstructive pulmonary disease Source: Annual Congress 2012 - Asthma and COPD: understanding through mechanisms Year: 2012
Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF Source: Eur Respir J 2002; 20: 1220-1227 Year: 2002
Expression of matrix metalloproteinases (MMPs) in primary spontaneous pneumothorax: MMP-9 as a potential biomarker for surgical intervention Source: International Congress 2017 – Thoracic surgery Year: 2017
Matrix metalloproteinases in tuberculosis Source: Eur Respir J 2011; 38: 456-464 Year: 2011
Matrix Metalloproteinases (MMPs) in patients with pulmonary tuberculosis (PT) and comorbid COPD Source: International Congress 2018 – Tuberculosis comorbidities Year: 2018
Correlation between matrix metalloproteinase-9 serum levels and disease severity in pulmonary tuberculosis patients Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Human macrophage elastase (MMP-12) expression in human emphysematous lungs: role in extracellular matrix remodelling in chronic obstructive pulmonary diseases (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 501s Year: 2001
MMP expression and abnormal lung permeability are important determinants of outcome in IPF Source: Eur Respir J 2009; 33: 77-84 Year: 2009